Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Buy” by Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $49.40.

A number of equities analysts have recently commented on the company. StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Stephens assumed coverage on Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. KeyCorp upped their price target on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Finally, BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th.

Simulations Plus Trading Up 0.1 %

Simulations Plus stock opened at $34.32 on Friday. The firm has a 50 day simple moving average of $30.46 and a 200 day simple moving average of $32.66. Simulations Plus has a 1-year low of $24.00 and a 1-year high of $51.22. The firm has a market capitalization of $689.49 million, a price-to-earnings ratio of 85.80 and a beta of 0.80.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the transaction, the director now owns 3,442,584 shares of the company’s stock, valued at $109,336,467.84. This represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 19.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC increased its holdings in shares of Simulations Plus by 15.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after buying an additional 290,414 shares during the period. Tributary Capital Management LLC boosted its holdings in Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after acquiring an additional 115,122 shares during the period. Royce & Associates LP grew its position in Simulations Plus by 28.8% during the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after acquiring an additional 53,092 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Simulations Plus by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock worth $20,128,000 after purchasing an additional 37,992 shares during the period. Finally, Congress Asset Management Co. lifted its position in Simulations Plus by 22.5% in the third quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock valued at $6,613,000 after purchasing an additional 37,914 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.